| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
|
N Engl J Med
|
2010
|
29.75
|
|
2
|
Increased survival with enzalutamide in prostate cancer after chemotherapy.
|
N Engl J Med
|
2012
|
20.79
|
|
3
|
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
|
BJU Int
|
2008
|
3.94
|
|
4
|
The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
|
J Urol
|
2013
|
2.33
|
|
5
|
New biomarkers in prostate cancer.
|
Oncology (Williston Park)
|
2014
|
2.22
|
|
6
|
Three year results of the prostatic urethral L.I.F.T. study.
|
Can J Urol
|
2015
|
1.92
|
|
7
|
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
|
BJU Int
|
2009
|
1.80
|
|
8
|
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift.
|
J Sex Med
|
2013
|
1.71
|
|
9
|
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience.
|
J Urol
|
2003
|
1.60
|
|
10
|
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature.
|
Eur Urol
|
2011
|
1.59
|
|
11
|
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.
|
J Clin Endocrinol Metab
|
2014
|
1.53
|
|
12
|
LHRH Agonists for the Treatment of Prostate Cancer: 2012.
|
Rev Urol
|
2012
|
0.96
|
|
13
|
Intermittent androgen deprivation therapy: redefining the standard of care?
|
Rev Urol
|
2010
|
0.91
|
|
14
|
Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
|
Clin Ther
|
2010
|
0.89
|
|
15
|
Use of a temporary prostatic stent after transurethral microwave thermotherapy reduced voiding symptoms and bother without exacerbating irritative symptoms.
|
Urology
|
2008
|
0.86
|
|
16
|
Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices.
|
Urology
|
2012
|
0.86
|
|
17
|
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
|
Expert Opin Drug Metab Toxicol
|
2015
|
0.84
|
|
18
|
Avoiding obsolescence in advanced prostate cancer management: a guide for urologists.
|
BJU Int
|
2015
|
0.79
|
|
19
|
Role of testosterone in managing advanced prostate cancer.
|
Urology
|
2012
|
0.76
|
|
20
|
Editorial comment. Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
|
Urology
|
2010
|
0.75
|
|
21
|
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
|
Prostate
|
2015
|
0.75
|
|
22
|
Editorial comment.
|
Urology
|
2011
|
0.75
|
|
23
|
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T.
|
Expert Rev Anticancer Ther
|
2014
|
0.75
|
|
24
|
Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
|
Can J Urol
|
2015
|
0.75
|
|
25
|
The changing landscape of urologic oncology: initiating systemic therapies, interventional skills, and clinical trials. Introduction.
|
Urol Oncol
|
2012
|
0.75
|
|
26
|
Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study.
|
Can J Urol
|
2017
|
0.75
|
|
27
|
Prostate Cancer Academy 2016: Presentation summaries.
|
Rev Urol
|
2016
|
0.75
|
|
28
|
Infusion therapy and implantables for the urologist.
|
Urol Clin North Am
|
2013
|
0.75
|
|
29
|
A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.
|
Postgrad Med
|
2013
|
0.75
|